AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23560810
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy starting immediately after discharge from the hospital
Trial: 19037616
Drug: Voice exercise/behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voice exercise/behavioral treatment
Trial: 12624520
Drug: Docetaxel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (75 mg/m2, d1) and 5-FU continuous infusion (200 mg/m2/d, d1-21, q3w)
Trial: 10685722
Drug: Perindopril 2
RxNorm normalized name: perindopril 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril 2 mg/Indapamide 0.625 mg (Per/Ind)
Trial: 2990329
Drug: 44 081
RxNorm normalized name: 4,4'-dinitrocarbanilide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 44 081 R.P. (0.2% solution, self-administered intranasally)
Trial: 27658417
Drug: Continue full
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continue full dose DMARDs and taper biologic therapy by 50% (Group 1)
Trial: 27658417
Drug: Taper both
RxNorm normalized name: caper berry extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taper both DMARDs and biologic therapy dose by 50% (Group 2)
Trial: 27658417
Drug: Taper DMARDs
RxNorm normalized name: caper berry extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taper DMARDs by 50% and stop biologic therapy (Group 3)
Trial: 27658417
Drug: Stop both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stop both DMARDs and biologic therapy (Group 4)
Trial: 27658417
Drug: Continue medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continue medications without change (Group 5)
Trial: 11834427
Drug: GH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH treatment (0.03 mU/kg/day)
Trial: 10794845
Drug: ApoAI cutoff
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ApoAI cutoff value of 1.50 g/L
Trial: 1488158
Drug: Glutamine supplementation
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glutamine supplementation in total parenteral nutrition
Trial: 1488158
Drug: Standard total
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard total parenteral nutrition without glutamine
Trial: 6702863
Drug: Thiazide treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiazide treatment
Trial: 6499703
Drug: Thiazide treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiazide treatment in hypokalaemic participants
Trial: 25304690
Drug: Probiotics and/or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics and/or synbiotics administration
Trial: 16257098
Drug: Quarter dose
RxNorm normalized name: Quarter Mate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quarter dose of ETEC vaccine
Trial: 2646187
Drug: Intravaginal application
RxNorm normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravaginal application of tablets containing 3 mg of prostaglandin E2
Trial: 29902969
Drug: BIS-guided propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BIS-guided propofol administration (target range 40-60)
Trial: 29902969
Drug: Weight-related propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weight-related propofol administration (2 mg/kg)
Trial: 29902969
Drug: BIS-guided propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BIS-guided propofol administration
Trial: 29902969
Drug: Weight-related propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weight-related propofol administration
Trial: 26287881
Drug: LASIK with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LASIK with concurrent high-fluence CXL
Trial: 23442755
Drug: Low-dose progestin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose progestin treatment (2.5 mg/day norethisterone acetate)
Trial: 23442755
Drug: Low-dose progestin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose progestin treatment
Trial: 21394001
Drug: Basal infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal infusion of 0.1% ropivacaine (5 ml/h for 6 hours)
Trial: 21394001
Drug: Repeated hourly
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated hourly bolus doses of 0.1% ropivacaine
Trial: 21394001
Drug: Basal infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal infusion vs. bolus doses comparison
Trial: 18349213
Drug: i.v. granisetron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. granisetron 1 mg
Trial: 9418686
Drug: No ovulation‐induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No ovulation‐induction drugs (spontaneous group)
Trial: 7516915
Drug: Cyclophosphamide 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide 4 g/m2 plus G-CSF (5 or 10 micrograms/kg)
Trial: 2963647
Drug: Mobilat ointment
RxNorm normalized name: Mobilan
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mobilat ointment (active treatment)
Trial: 22205355
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with an angiotensin-converting inhibitor and receptor blocker
Trial: 22205355
Drug: Inhibitor alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhibitor alone
Trial: 22205355
Drug: Inhibitor-blocker treatment
RxNorm normalized name: ACE inhibitors and calcium channel blockers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhibitor-blocker treatment
Trial: 20452823
Drug: Pramipexole (0.125-1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole (0.125-1.0 mg three times per day)
Trial: 18665164
Drug: Capecitabine 1250
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1250 mg m(‐2) two times daily on days 1‐14 every 3 weeks
Trial: 18665164
Drug: S-1 40‐60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 40‐60 mg two times daily according to body surface area on days 1‐28 every 6 weeks
Trial: 15567880
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist (2 mg/2 ml, 1 mg/ml, 0.5 mg/ml, 0.5 mg/0.5 ml or 0.25 mg/ml)
Trial: 12759654
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose multidetector CT (30 mA protocol)
Trial: 12759654
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose multidetector CT (10 mA protocol)
Trial: 3526155
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (cephalothin, gentamicin, and carbenicillin)
Trial: 31907104
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment only (M)
Trial: 31179007
Drug: 3-day antibiotic
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-day antibiotic treatment
Trial: 31050078
Drug: 7-day antibiotic
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day antibiotic treatment
Trial: 28681388
Drug: Natalizumab (NTZ)
RxNorm normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Natalizumab (NTZ) treatment
Trial: 21316267
Drug: Levetiracetam (LEV)
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levetiracetam (LEV) 1000 mg/day
Trial: 21316267
Drug: Carbamazepine-CR (CBZ-CR)
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbamazepine-CR (CBZ-CR) 400 mg/day
Trial: 15295223
Drug: PncCRM vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PncCRM vaccine
Trial: 9683300
Drug: oral clodronate
RxNorm normalized name: Clodronic acid
DrugBank: Clodronic acid (DB00720)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral clodronate 1600 mg daily for 3 years
Trial: 2962321
Drug: Heparin 5,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin 5,000 International units per liter added to warm isotonic Ringer's lactate solution
Trial: 2962321
Drug: No heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No heparin added to warm isotonic Ringer's lactate solution
Trial: 23761104
Drug: Intraduodenal glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraduodenal glucose infusion of 30 g/150 mL water plus 3 g 3‐O‐methylglucose (3‐OMG)
Trial: 23761104
Drug: Intraduodenal glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraduodenal glucose infusion of 30 g/150 mL water plus 3 g 3‐OMG
Trial: 22164503
Drug: Routine liver
RxNorm normalized name: LIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine liver protection drugs
Trial: 19407949
Drug: Auricular points
RxNorm normalized name: brilliant green
DrugBank: Brilliant green cation (DB11279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Auricular points sticking-pressing (APSP), pellets pressed 4 times daily
Trial: 7781464
Drug: Atropine (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (7 micrograms/kg) during active gas infusion
Trial: 7781464
Drug: Placebo during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo during active gas infusion
Trial: 7781464
Drug: Sham gas
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham gas administration
Trial: 7781464
Drug: Active gas
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active gas infusion
Trial: 2146577
Drug: Ondansetron 3
RxNorm normalized name: ondansetron 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 3 x 8 mg/day for a maximum of 10 cycles
Trial: 356241
Drug: Proquazone (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proquazone (900 mg daily)
Trial: 28527564
Drug: Peri- and
RxNorm normalized name: casanthranol / docusate sodium Oral Capsule [Peri-Colace]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peri- and postoperative antibiotic prophylaxis (POAP) from the day of operation until the fifth day postoperatively
Trial: 28527564
Drug: Perioperative antibiotic
RxNorm normalized name: ENSURE SURGERY PERIOPERATIVE KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative antibiotic prophylaxis (PEAP) only
Trial: 28527564
Drug: Perioperative antibiotic
RxNorm normalized name: ENSURE SURGERY PERIOPERATIVE KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative antibiotic prophylaxis and increased local antiseptic care (PAPAC)
Trial: 24350597
Drug: Moderate-dose endurance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-dose endurance training (MOD, 300 kcal/day)
Trial: 24350597
Drug: High-dose endurance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose endurance training (HIGH, 600 kcal/day)
Trial: 20455886
Drug: Cholecalciferol (60,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol (60,000 IU D3/week for 8 weeks followed by 60,000 IU/month for 4 months) with 1 g of elemental calcium daily
Trial: 16239760
Drug: Olanzapine (exact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (exact dosage and duration not specified)
Trial: 10463251
Drug: Iprazochrome 15
RxNorm normalized name: iprazochrome
DrugBank: Iprazochrome (DB13541)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iprazochrome 15 mg daily in three equal doses for eight weeks
Trial: 9017568
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of treatment on a fee-for-service basis
Trial: 9017568
Drug: Transfer to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfer to another treatment provider
Trial: 6685516
Drug: Piretanide 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piretanide 12 mg
Trial: 25222799
Drug: Cognitive-behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral treatment (Coping Cat) for 12 weeks
Trial: 25222799
Drug: Medication (sertraline)
RxNorm normalized name: Medicated Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (sertraline) for 12 weeks
Trial: 25222799
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of cognitive-behavioral treatment and medication for 12 weeks
Trial: 25222799
Drug: Pill placebo
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pill placebo for 12 weeks
Trial: 16529161
Drug: Renal replacement
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renal replacement therapy (haemodialysis) with polysulphone membranes
Trial: 11387733
Drug: Clinician-Administered PTSD
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinician-Administered PTSD Scale (CAPS)
Trial: 31913927
Drug: 0.3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg ketamine
Trial: 30009223
Drug: 0.4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg/kg ketamine
Trial: 24508795
Drug: Cross-linking twice
RxNorm normalized name: riboflavin 5'-phosphate
DrugBank: Flavin mononucleotide (DB03247)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cross-linking twice (Group B)
Trial: 18207016
Drug: Modified-release prednisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified-release prednisone tablet taken at bedtime, released with a delay of 4 hours after ingestion.
Trial: 18207016
Drug: Immediate-release prednisone
RxNorm normalized name: prednisone Delayed Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release prednisone tablet taken in the morning as an active comparator.
Trial: 18207016
Drug: Immediate-release prednisone
RxNorm normalized name: prednisone Delayed Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release prednisone
Trial: 15688278
Drug: Recombinant HIV-1
RxNorm normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant HIV-1 envelope glycoprotein subunit (rgp120) vaccine
Trial: 10774461
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with methotrexate (MTX)
Trial: 29026977
Drug: PVP (PROCEED®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PVP (PROCEED® Ventral Patch)
Trial: 25192498
Drug: Dersalazine sodium
RxNorm normalized name: mesalazine
DrugBank: Dersalazine (DB06251)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dersalazine sodium 1200 mg/12 h
Trial: 25192498
Drug: Mesalazine 1200
RxNorm normalized name: mesalamine 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalazine 1200 mg/12 h
Trial: 21524314
Drug: High fiber,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High fiber, relatively high carbohydrate diet (50% carbohydrate, > 35 g total dietary fiber, 20% protein)
Trial: 17062305
Drug: Sustained-release glipizide
RxNorm normalized name: glipizide Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release glipizide (GSR) 10 mg PO QD
Trial: 17062305
Drug: Immediate-release glipizide
RxNorm normalized name: glipizide Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release glipizide (GIR) 5 mg PO BID
Trial: 17062305
Drug: Sustained-release glipizide
RxNorm normalized name: glipizide Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release glipizide (GSR)
Trial: 17062305
Drug: Immediate-release glipizide
RxNorm normalized name: glipizide Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release glipizide (GIR)
Trial: 10880063
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care preparation for child's BMT
Trial: 8918625
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron saccharate (10-100 mg)
Trial: 8918625
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron saccharate (100 mg)
Trial: 8918625
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron saccharate (10-40 mg)
Trial: 1417433
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy (alone or in combination with medication)
Trial: 1417433
Drug: Imipramine hydrochloride
RxNorm normalized name: Imipramine Hydrochloride
DrugBank: Imipramine (DB00458)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Imipramine hydrochloride pharmacotherapy
Trial: 1417433
Drug: Combined cognitive-pharmacotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined cognitive-pharmacotherapy
Trial: 1819153
Drug: Combination tablet
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination tablet (40 mg frusemide and 5 mg amiloride)
Trial: 1391258
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no diuretics)
Trial: 24380874
Drug: Behavioural voice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioural voice therapy
Trial: 24380874
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment (after eight week assessment)
Trial: 20384746
Drug: Tamoxifen tablets
RxNorm normalized name: tamoxifen Oral Tablet
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen tablets postoperatively according to a standard protocol
Trial: 16061590
Drug: Montelukast (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (5 mg, once daily)
Trial: 16061590
Drug: Fluticasone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone (100 microg, twice daily)
Trial: 2180658
Drug: Tofu-based frozen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofu-based frozen dessert (TFD) containing high-fructose corn syrups
Trial: 2180658
Drug: Dairy-based sucrose-sweetened
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dairy-based sucrose-sweetened ice cream (IC)
Trial: 19957871
Drug: Pool-aquatic program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pool-aquatic program in warm water (three weekly 60-min sessions for four months)
Trial: 12852237
Drug: Chemotherapy (drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (drugs such as cyclophosphamide, 5-fluorouracil, and doxorubicin)
Trial: 28941196
Drug: Vortioxetine (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine (single rising doses)
Trial: 28941196
Drug: Vortioxetine (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine (multiple doses)
Trial: 22277837
Drug: Chemotherapy (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (standard docetaxel or pemetrexed regimens)
Trial: 20729242
Drug: Adjuvant temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adjuvant temozolomide alone (150 mg/m²/day, 7/14‐day schedule)
Trial: 20729242
Drug: Adjuvant temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adjuvant temozolomide plus thalidomide (400 mg/day)
Trial: 20729242
Drug: Adjuvant temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adjuvant temozolomide plus isotretinoin (100 mg/m²/day)
Trial: 20729242
Drug: Adjuvant temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adjuvant temozolomide plus celecoxib (400 mg twice daily)
Trial: 20729242
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment (dose-dense temozolomide with cytostatic agents)
Trial: 11534926
Drug: Imipramine maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine maintenance treatment (IMI-IMI)
Trial: 11534926
Drug: Placebo maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo maintenance treatment (PBO-PBO)
Trial: 3065737
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIg) 400 mg/kg body weight every 3 weeks for a year
Trial: 29794557
Drug: Ibudilast (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibudilast (50 mg bid)
Trial: 23532241
Drug: Azithromycin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (250 mg daily) for 12 months
Trial: 23532241
Drug: Azithromycin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (250 mg daily)